Extract
Lung transplantation has become an invaluable approach for the treatment of end-stage respiratory diseases. However, survival after lung transplant remains limited due to chronic lung allograft dysfunction (CLAD), a fibrotic process affecting the airway and/or parenchymal compartments of the lung graft leading to a significant and persistent deterioration in lung function [1, 2]. With our accelerating understanding of CLAD, it has become evident that CLAD is a heterogeneous process comprised of multiple patterns of physiological and radiological features, which have strong implications for post-CLAD survival [3]. In a consensus document published by the International Society for Heart and Lung Transplantation (ISHLT) [2], CLAD remains defined as substantial and persistent decline (≥20%) in forced expiratory volume in 1 s (FEV1) from baseline, not explained by other conditions.
Abstract
In lung transplant recipients with suspected restrictive allograft syndrome/mixed phenotype and a preserved forced vital capacity, accurate phenotyping requires routine measurements of total lung capacity https://bit.ly/3e2qxdP
Footnotes
Conflict of interest: L. Levy has nothing to disclose.
Conflict of interest: E. Huszti has nothing to disclose.
Conflict of interest: G. Berra has nothing to disclose.
Conflict of interest: B. Renaud-Picard has nothing to disclose.
Conflict of interest: M. Kawashima has nothing to disclose.
Conflict of interest: A. Takahagi has nothing to disclose.
Conflict of interest: S. Moshkelgosha has nothing to disclose.
Conflict of interest: R. Ghany has nothing to disclose.
Conflict of interest: E. Fuchs has nothing to disclose.
Conflict of interest: C-W. Chow has nothing to disclose.
Conflict of interest: S. Keshavjee has nothing to disclose.
Conflict of interest: L.G. Singer has nothing to disclose.
Conflict of interest: J. Tikkanen has nothing to disclose.
Conflict of interest: T. Martinu has nothing to disclose.
Support statement: This research was supported in part by a grant from The Canadian Institutes of Health Research (to T. Martinu), a grant from The Physicians’ Services Inc. Foundation (to L. Levy and T. Martinu) and by a Cystic Fibrosis Canada grant (to L. Levy). Funding information for this article has been deposited with the Crossref Funder Registry.
- Received September 11, 2020.
- Accepted February 28, 2021.
- Copyright ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org